本报告期医药生物行业指数跌幅为1.02%，在申万31 个一级行业中位居第2，跑赢沪深300 指数（-5.13%）。从子行业来看，医药生物三级行业中，疫苗、医药流通、体外诊断板块涨幅居前，涨幅分别为11.23%、9.73%、3.24%；医院、线下药店、血液制品板块跌幅居前，跌幅分别为15.69%、12.13%、7.53%。估值方面，截止2022 年3 月18 日，医药生物行业PE（TTM 整体法，剔除负值）为28.69x（上期29.22x），低于负一倍标准差

新冠疫苗接种进入常态化，挤兑因素不断消除。目前国内加强针覆盖率达到40%左右。自2022 年开年以来，刨除春节因素外，新冠疫苗每日接种量维持在500 万剂左右，远低于高峰值2400 万剂，新冠接种挤兑因素不断消除。按照500 万剂/日接种量测算，我们预计加强针接种将在22 年上半年完成 。

Research process is defined by creating multiple algorithms considering the problem statement, we classify the market into mainly market driven by industry performance, market driven by economic political performance and market driven by consumer sentiments Information gathered is evaluated on the above level using our extensive research process and reevaluated to generate better results

The scope of the research study titled “Global Surgical Microscopes Market” is aimed at assessing the market potential for both conventional microscopes and advanced microscopes. The following are the types of approaches in which the surgical microscopes market was estimated, and its growth potential for the forecast period was evaluated:

Preimplantation genetic diagnosis (PGD) is performed among couples with a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates. As per a research study published by MDPI, embryo aneuploidy is one of the significant reasons for IVF failure enhancing the importance of the preimplantation genetic testing for aneuploidies as a mode of selecting healthy embryos with normal chromosomes. The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.

Over the last few years, the global pharmaceutical industry has undergone significant changes. In recent years, the cost of drugs has been increasing rapidly, a majority of which is contributed by funds allocated to research and development. According to a report published by Congressional Budget Office (CBO) in April 2021, titled, ‘Research and Development in the Pharmaceutical Industry,’ the U.S. pharmaceutical industry’s R&D expenditure in 2019 was nearly $83 billion, spanning a range of activities such as drug discovery, conducting clinical tests, and drug innovation, among others. Additionally, the report also states that the budget share allocated by pharmaceutical companies toward research and development has also increased. The following table shows a rough estimate of the annual R&D expenditure of pharmaceutical companies.

Molecular diagnostics encompasses a rapidly evolving range of assays and systems that facilitate pathogen detection, viral load estimation, antibiotic and antiviral therapy selection, diagnosis of cancer, and other diseases, by the detection and analysis of proteins and nucleic acid sequences. Molecular diagnostics also offer prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy. Molecular diagnostics has evolved to be an integrative aspect of healthcare routines by providing most laboratory tests in infectious disease and genetics, and a continuously increasing number of tests in oncology. The massively parallel methods that have now transcended molecular diagnostics allow sequencing of entire genomes at very low costs. The sequenced databases within and between species provide the information necessary for the development of sensitive and specific diagnostic assays. The effect of extensive sequencing procedures has led to most microorganisms today being classified on the basis of sequence rather than phenotype. A presumptive diagnosis is made if a microbial sequence is present where it should not be.

The research provides an overview of all the M&As and divestitures in the medtech industry during the study period. The M&As focus on three primary areas: The clinical specialty areas where the M&As occur. The purpose behind these deals. oThe impact of the consolidated landscape on healthcare providers, payers, patients, and other market players.